Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesNSE:CORONA +0.37%18 Days Payable is 202.60 as of Mar. 2026, which is 10% above its 10-year median of 183.41. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Corona Remedies ranks better than 88.89% on this metric.
The historical rank and industry rank for Corona Remedies's Days Payable or its related term are showing as below:
NSE:CORONA'
s Days Payable Range Over the Past 10 Years
Min: 163.28 Med: 183.41 Max: 259.15
Current: 259.15
During the past 4 years, Corona Remedies's highest Days Payable was 259.15. The lowest was 163.28. And the median was 183.41.
NSE:CORONA's Days Payable is ranked better than 88.89% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.28
vs NSE:CORONA: 259.15
Corona Remedies's Days Payable
increased
from Dec. 2024 (188.94) to Mar. 2026 (202.60).
It may suggest that Corona Remediesdelayed paying its suppliers.
The historical data trend for Corona Remedies's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CORONA vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Corona Remedies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's Days Payable distribution charts can be found below:
* The bar in red indicates where Corona Remedies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Corona Remedies's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corona Remedies (NSE:CORONA) has a Days Payable of 202.60 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Corona Remedies and its competitors. This is 10% above median its historical median of 183.41. Over the past decade, Corona Remedies' Days Payable has ranged from 163.28 to 259.15. According to the industry distribution chart, Corona Remedies ranks #103 out of 927 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Corona Remedies' Days Payable too high?
Corona Remedies' current Days Payable of 202.60 is 10% above median its 10-year median of 183.41. Over the past 10 years, this metric has ranged from a low of 163.28 to a high of 259.15. The Drug Manufacturers industry median Days Payable is 90.28. Corona Remedies' value of 202.60 is 124.4% above this industry median. Based on the distribution chart, Corona Remedies ranks #103 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #103 out of 927 companies for Days Payable. This places Corona Remedies in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.28. Corona Remedies' value of 202.60 is 124.4% above this benchmark. Historically, Corona Remedies' own Days Payable has ranged from 163.28 to 259.15 over the past decade. While the company's 10-year median is 183.41 vs. the industry median of 90.28, Corona Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current Days Payable of 202.60 is 124.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current Days Payable is 202.60, which is 10% above median its own 10-year median of 183.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Days Payable of 202.60. The current Days Payable is 202.60, which is 10% above median its 10-year median of 183.41 and 124.4% above the Drug Manufacturers industry median of 90.28. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Days Payable is 202.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for NSE:CORONA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CORONA has been successfully added to your 
